--- title: "14:15 ETSHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS" type: "News" locale: "en" url: "https://longbridge.com/en/news/282082448.md" description: "Class Action Attorney Juan Monteverde is investigating mergers involving Kezar Life Sciences (KZR), Centessa Pharmaceuticals (CNTA), Affinity Bancshares (AFBI), and Apellis Pharmaceuticals (APLS). Shareholders of KZR are expected to receive $6.955 per share, CNTA $38.00 per share, AFBI $23.00 per share, and APLS $41.00 per share, along with contingent value rights in some cases. The firm has a successful track record in recovering funds for shareholders and offers free consultations for those concerned about these transactions." datetime: "2026-04-08T18:17:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282082448.md) - [en](https://longbridge.com/en/news/282082448.md) - [zh-HK](https://longbridge.com/zh-HK/news/282082448.md) --- # 14:15 ETSHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS , /PRNewswire/ -- **Class Action Attorney** Juan Monteverde **with** Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a **Top 50 Firm** in the 2025 ISS Securities Class Action Services Report. We are headquartered at the **Empire State Building** in New York City and are investigating - **Kezar Life Sciences, Inc. (NASDAQ: KZR)** related to its sale to Aurinia Pharmaceuticals Inc. Under the terms of the proposed transaction, Kezar shareholders are expected to receive $6.955 per share in cash and one non-transferable contingent value right. **Click here for more information https://monteverdelaw.com/case/kezar-life-sciences-inc/****.** **It is free and there is no cost or obligation to you.** - **Centessa Pharmaceuticals plc (NASDAQ: CNTA)** related to its sale to Eli Lilly and Company. Under the terms of the proposed transaction, Centessa shareholders are expected to receive $38.00 per share in cash and one non-transferable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. **Click here for more information** **https://monteverdelaw.com/case/centessa-pharmaceuticals-plc/****.** **It is free and there is no cost or obligation to you.** - **Affinity Bancshares, Inc. (NASDAQ: AFBI)** related to its sale to Fidelity Bancshares (N.C.), Inc. Under the terms of the proposed transaction, Affinity shareholders are expected to receive $23.00 per share in cash. **Click here for more information https://monteverdelaw.com/case/affinity-bancshares-inc-2/****.** **It is free and there is no cost or obligation to you.** - **Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)** related to its sale to Biogen, Inc. Under the terms of the proposed transaction, Apellis shareholders are expected to receive $41.00 per share in cash and a non-transferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. **Click here for more info** **https://monteverdelaw.com/case/apellis-pharmaceuticals-inc/****.** **It is free and there is no cost or obligation to you.** **NOT ALL LAW FIRMS ARE THE SAME.** Before you hire a law firm, you should talk to a lawyer and ask: 1. Do you file class actions and go to Court? 2. When was the last time you recovered money for shareholders? 3. What cases did you recover money in and how much? **About Monteverde & Associates PC** Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. **No company, director or officer is above the law.** If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our **website** or contact Juan Monteverde, Esq. either via e-mail at **\[email protected\]** or by telephone at (212) 971-1341. Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC **The Empire State Building **350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America \[email protected\] Tel: (212) 971-1341 Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter. SOURCE Monteverde & Associates PC ### Related Stocks - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [CNTA.US](https://longbridge.com/en/quote/CNTA.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [AFBI.US](https://longbridge.com/en/quote/AFBI.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [APLS.US](https://longbridge.com/en/quote/APLS.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [KZR.US](https://longbridge.com/en/quote/KZR.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) ## Related News & Research - [Apellis Completes Biogen Merger and Goes Private](https://longbridge.com/en/news/286424730.md) - [Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push](https://longbridge.com/en/news/286623100.md) - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md) - [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)